CSL Change in Accounts Receivable 2017-2024 | CSLLY

CSL change in accounts receivable for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CSL annual change in accounts receivable for 2024 was $-0.766B, a 2835.71% decline from 2023.
  • CSL annual change in accounts receivable for 2023 was $0.028B, a 162.22% decline from 2022.
  • CSL annual change in accounts receivable for 2022 was $-0.045B, a 223.29% decline from 2021.

CSL Change in Accounts Receivable 2017-2024 | CSLLY

  • CSL annual change in accounts receivable for 2024 was $-0.766B, a 2835.71% decline from 2023.
  • CSL annual change in accounts receivable for 2023 was $0.028B, a 162.22% decline from 2022.
  • CSL annual change in accounts receivable for 2022 was $-0.045B, a 223.29% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$231.3B
Amgen (AMGN)$153.3B
Gilead Sciences (GILD)$137.2B
Vertex Pharmaceuticals (VRTX)$96.3B
Bristol Myers Squibb (BMY)$92.3B
GSK (GSK)$76.6B
Regeneron Pharmaceuticals (REGN)$60.4B
Alnylam Pharmaceuticals (ALNY)$57B
Argenex SE (ARGX)$41.1B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$20.8B
Insmed (INSM)$20.7B
Biogen (BIIB)$18.7B
Incyte (INCY)$15.3B
Illumina (ILMN)$14.7B
Genmab (GMAB)$14.6B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.6B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.1B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Exact Sciences (EXAS)$8.2B
Bio-Techne Corp (TECH)$7.9B
Roivant Sciences (ROIV)$7.9B
Halozyme Therapeutics (HALO)$7.7B
Legend Biotech (LEGN)$6.9B